



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Lie-Fen SHYUR et al.

Serial No.:

09/654,652

Filed: September 05, 2000

A Truncated Form of Fibrobacter Succinogenes

1,3-1,4-Beta-D-Glucanase

With

Improved

Enzymatic Activity And Thermo-Tolerance

Examiner:

JUL 2 4 2001

**TECH CENTER 1600/2900** 

Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

July 16, 2001 (Date of Deposit)

Kent H. Cheng licant, assignee or Register

Date of Signature

Assistant Commissioner for Patents Washington, DC 20231

**BOX: SEQUENCE LISTING** 

## SUBMISSION OF SEQUENCE LISTING AND STATEMENT UNDER 37 C.F.R. §1.821(f)

SIR:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 15, 2001, a copy of which is enclosed, Applicants submit herewith a sequence listing for the nucleotide sequence and/or amino acid sequence disclosed in the above-identified patent application.

## **REMARKS**

A copy of the sequence listing in computer readable form is also enclosed. The content

of enclosed paper and computer readable copies of the sequence listing are the same, and the submission contains no new matter.

Respectfully submitted,

COHEN, PONTANI, LIEBERMAN & PAVANE

V \_\_\_\_/ Kent H\_Ch

Reg. No. 33,849

551 Fifth Avenue, Suite 1210 New York, New York 10176

(212) 687-2770

Dated: July 16, 2001

>		Application No.	Applicant(s)	RECEIV	
O		Application No.	Applicant(s)		
	Notice to Comply	Examiner	Art Unit	<u> </u>	
	E S		TE	ECH CENTER 160	
	NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS				
	CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES				
	Applicant must file the items indicated belo is attached to avoid abandonment under 35 provisions of 37 CFR 1.136(a)).	oplicant must file the items indicated below within the time period set the Office action to which the Notice attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the ovisions of 37 CFR 1.136(a)).			
	The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):				
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).				
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).				
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).				
	7. Other:				
	Applicant Must Provide:  ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
	$\square$ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.				
	$\boxtimes$ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
	For questions regarding compliance	to these requirements, plea	ase contact:		

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentin Software Program Support